Man Group’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,356
| Closed | -$219K | – | 2615 |
|
|
2026
Q1 | $219K | Buy |
+7,356
| New | +$220K | ﹤0.01% | 2286 |
|
|
2025
Q4 | – | Sell |
-29,727
| Closed | -$710K | – | 2476 |
|
|
2025
Q3 | $710K | Sell |
29,727
-109,317
| -79% | -$2.06M | ﹤0.01% | 1767 |
|
|
2025
Q2 | $2.06M | Buy |
139,044
+90,265
| +185% | +$1.5M | ﹤0.01% | 1405 |
|
|
2025
Q1 | $874K | Sell |
48,779
-39,462
| -45% | -$801K | ﹤0.01% | 1617 |
|
|
2024
Q4 | $1.54M | Buy |
88,241
+62,798
| +247% | +$1.11M | ﹤0.01% | 1391 |
|
|
2024
Q3 | $356K | Sell |
25,443
-73,219
| -74% | -$763K | ﹤0.01% | 1736 |
|
|
2024
Q2 | $811K | Sell |
98,662
-18,939
| -16% | -$128K | ﹤0.01% | 1562 |
|
|
2024
Q1 | $907K | Buy |
+117,601
| New | +$992K | ﹤0.01% | 1583 |
|
|
2023
Q1 | – | Sell |
-21,300
| Closed | -$453K | – | 1575 |
|
|
2022
Q4 | $448K | Buy |
21,300
+2,800
| +15% | +$59.3K | ﹤0.01% | 1540 |
|
|
2022
Q3 | $456K | Buy |
+18,500
| New | +$478K | ﹤0.01% | 1548 |
|
|
2022
Q2 | – | Sell |
-9,500
| Closed | -$245K | – | 2408 |
|
|
2022
Q1 | $245K | Buy |
+9,500
| New | +$252K | ﹤0.01% | 1850 |
|
|
2021
Q1 | – | Sell |
-53,777
| Closed | -$1.47M | – | 2002 |
|
|
2020
Q4 | $1.47M | Buy |
53,777
+200
| +0.4% | +$4.67K | 0.01% | 1302 |
|
|
2020
Q3 | $989K | Buy |
53,577
+4,807
| +10% | +$93.4K | ﹤0.01% | 1376 |
|
|
2020
Q2 | $996K | Sell |
48,770
-7,207
| -13% | -$115K | 0.01% | 1272 |
|
|
2020
Q1 | $817K | Sell |
55,977
-3,635
| -6% | -$54.7K | 0.01% | 1162 |
|
|
2019
Q4 | $846K | Hold |
59,612
| – | – | ﹤0.01% | 1518 |
|
|
2019
Q3 | $691K | Sell |
59,612
-300
| -0.5% | -$4.96K | ﹤0.01% | 1512 |
|
|
2019
Q2 | $1.2M | Sell |
59,912
-1,633
| -3% | -$32.2K | ﹤0.01% | 1467 |
|
|
2019
Q1 | $1.39M | Sell |
61,545
-3,067
| -5% | -$67.8K | 0.01% | 1474 |
|
|
2018
Q4 | $1.46M | Sell |
64,612
-7,130
| -10% | -$177K | 0.01% | 1334 |
|
|
2018
Q3 | $2.06M | Buy |
71,742
+11,455
| +19% | +$327K | 0.01% | 1409 |
|
|
2018
Q2 | $1.64M | Buy |
60,287
+7,375
| +14% | +$196K | 0.01% | 1441 |
|
|
2018
Q1 | $1.18M | Buy |
+52,912
| New | +$1.26M | 0.01% | 1465 |
|
Other funds holding TVTX
JT
PA
NAMI
Man Group's TVTX Position: Q2 2026 in Review
Man Group sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 7,356 shares — an estimated $219K sold.
Man Group first reported a position in TVTX in Q1 2018 and held it in 23 quarters. The position peaked at $2.06M in Q3 2018. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- Man Group reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
- Man Group sold 7,356 Travere Therapeutics shares in Q2 2026, an estimated $219K.
- Man Group first reported a position in Travere Therapeutics in Q1 2018 and held it in 23 quarters.
- Man Group's Travere Therapeutics position peaked at $2.06M in Q3 2018.
- 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.